Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Anesthesia
Erschienen in: Journal of Anesthesia 3/2016

06.04.2016 | Editorial

Adrenoceptor modulators and cancer progression

verfasst von: Kazuyoshi Hirota

Erschienen in: Journal of Anesthesia | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Excerpt

Several recent articles published in the Journal of Anesthesia suggest that anesthetic agents, sedatives, and opioids may affect cancer relapse, metastasis, and recurrence [1‐3]. In addition, we use adrenoceptor agonists or antagonists in the perioperative setting for hemodynamic maintenance in patients undergoing radical cancer surgery. Moreover, the highly selective α2-agonist dexmedetomidine is often used as a sedative in the intensive care unit and sometimes as an adjuvant in paravertebral block to reduce postoperative opioid consumption and the incidence of nausea and vomiting [4]. However, do we know whether these agents affect prognosis in cancer patients? In this editorial, effects of adrenoceptor modulators on cancer are discussed. …
Literatur
1.
Niwa H, Rowbotham DJ, Lambert DG, Buggy DJ. Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery? J Anesth. 2013;27:731–41.CrossRefPubMed
2.
Nomura Y, Kawaraguchi Y, Sugimoto H, Furuya H, Kawaguchi M. Effects of morphine and fentanyl on 5-fluorouracil sensitivity in human colon cancer HCT116 cells. J Anesth. 2014;28:298–301.CrossRefPubMed
3.
Nishiwada T, Kawaraguchi Y, Uemura K, Sugimoto H, Kawaguchi M. Effect of sevoflurane on human hepatocellular carcinoma HepG2 cells under conditions of high glucose and insulin. J Anesth. 2015;29:805–8.CrossRefPubMed
4.
Mohta M, Kalra B, Sethi AK, Kaur N. Efficacy of dexmedetomidine as an adjuvant in paravertebral block in breast cancer surgery. J Anesth. 2016;30:252–60.CrossRefPubMed
5.
6.
Tang J, Li Z, Lu L, Lu L, Cho CH. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23:533–42.CrossRefPubMed
7.
Stiles JM, Amaya C, Rains S, Diaz D, Pham R, Battiste J, Modiano JF, Kokta V, Boucheron LE, Mitchell DC, Bryan BA. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One. 2013;8:e60021.CrossRefPubMedPubMedCentral
8.
De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P. Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc. 2013;88:1196–203.CrossRefPubMed
9.
McCourt C, Coleman HG, Murray LJ, Cantwell MM, Dolan O, Powe DG, Cardwell CR. β-Blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. Br J Dermatol. 2014;170:930–8.CrossRefPubMed
10.
Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, Vergote I, Plante M, Pfisterer J, AGO study group; NCIC-CTG study group; EORTC-GCG study group. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer: a combined analysis of two prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol. 2013;129:463–6.CrossRefPubMed
11.
Jansen L, Below J, Chang-Claude J, Brenner H, Hoffmeister M. Beta blocker use and colorectal cancer risk: population-based case-control study. Cancer (Phila). 2012;118:3911–9.CrossRef
12.
Sørensen GV, Ganz PA, Cole SW, Pedersen LA, Sørensen HT, Cronin-Fenton DP, Garne JP, Christiansen PM, Lash TL, Ahern TP. Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol. 2013;31:2265–72.CrossRefPubMedPubMedCentral
13.
Livingstone E, Hollestein LM, van Herk-Sukel MP, van de Poll-Franse L, Nijsten T, Schadendorf D, de Vries E. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. Eur J Cancer. 2013;49:3863–71.CrossRefPubMed
14.
Hicks BM, Murray LJ, Powe DG, Hughes CM, Cardwell CR. β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Ann Oncol. 2013;24:3100–6.CrossRefPubMed
15.
Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V. Perioperative β-blocker use and survival in lung cancer patients. J Clin Anesth. 2014;26:106–17.CrossRefPubMed
16.
Cardwell CR, Coleman HG, Murray LJ, Entschladen F, Powe DG. Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort. Int J Epidemiol. 2013;42:1852–61.CrossRefPubMed
17.
Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando-Lemaire V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila). 2012;5:1007–14.CrossRef
18.
Monami M, Filippi L, Ungar A, Sgrilli F, Antenore A, Dicembrini I, Bagnoli P, Marchionni N, Rotella CM, Mannucci E. Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin. 2013;29:369–78.CrossRefPubMed
19.
Katsogiannou M, El Boustany C, Gackiere F, Delcourt P, Athias A, Mariot P, Dewailly E, Jouy N, Lamaze C, Bidaux G, Mauroy B, Prevarskaya N, Slomianny C. Caveolae contribute to the apoptosis resistance induced by the α(1A)-adrenoceptor in androgen-independent prostate cancer cells. PLoS One. 2009;4:e7068.CrossRefPubMedPubMedCentral
20.
Hori Y, Ishii K, Kanda H, Iwamoto Y, Nishikawa K, Soga N, Kise H, Arima K, Sugimura Y. Naftopidil, a selective α1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila). 2011;4:87–96.CrossRef
21.
Yamada D, Nishimatsu H, Kumano S, Hirano Y, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Kume H, Homma Y. Reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor. Int J Urol. 2013;20:1220–7.CrossRefPubMed
22.
Masachika E, Kanno T, Nakano T, Gotoh A, Nishizaki T. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking. Anticancer Res. 2013;33:887–94.PubMed
23.
Fuchs R, Schwach G, Stracke A, Meier-Allard N, Absenger M, Ingolic E, Haas HS, Pfragner R, Sadjak A. The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT. Anticancer Res. 2015;35:31–8.PubMedPubMedCentral
24.
Bruzzone A, Piñero CP, Rojas P, Romanato M, Gass H, Lanari C, Lüthy IA. α2-Adrenoceptors enhance cell proliferation and mammary tumor growth acting through both the stroma and the tumor cells. Curr Cancer Drug Targets. 2011;11:763–74.CrossRefPubMed
25.
Lamkin DM, Sung HY, Yang GS, David JM, Ma JC, Cole SW, Sloan EK. α2-Adrenergic blockade mimics the enhancing effect of chronic stress on breast cancer progression. Psychoneuroendocrinology. 2015;51:262–70.CrossRefPubMedPubMedCentral
26.
Griwan MS, Karthikeyan YR, Kumar M, Singh BJ, Singh SK. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urol Ann. 2014;6:181–6.CrossRefPubMedPubMedCentral
27.
Huang J, He F, Huang M, Liu X, Xiong Y, Huang Y, Zhu L, Yang Y, Xu X, Yuan M. Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents. Eur J Med Chem. 2015;96:83–91.CrossRefPubMed
28.
Bruzzone A, Piñero CP, Castillo LF, Sarappa MG, Rojas P, Lanari C, Lüthy IA. Alpha-2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol. 2008;155:494–504.CrossRefPubMedPubMedCentral
29.
Shkurnikov MY, Galatenko VV, Lebedev AE, Podol’skii VE, Tonevitskii EA, Mal’tseva DV. On statistical relationship between ADRA2A expression and the risk of breast cancer relapse. Bull Exp Biol Med. 2014;157:454–8.CrossRefPubMed
30.
Lamkin DM, Sung HY, Yang GS, David JM, Ma JC, Cole SW, Sloan EK. α2-Adrenergic blockade mimics the enhancing effect of chronic stress on breast cancer progression. Psychoneuroendocrinology. 2015;51:262–70.CrossRefPubMedPubMedCentral
31.
Szpunar MJ, Burke KA, Dawes RP, Brown EB, Madden KS. The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure. Cancer Prev Res (Phila). 2013;6:1262–72.CrossRef
32.
Levy I, Horvath A, Azevedo M, de Alexandre RB, Stratakis CA. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. Curr Opin Pharmacol. 2011;11:689–97.CrossRefPubMedPubMedCentral
Metadaten
Titel
Adrenoceptor modulators and cancer progression
verfasst von
Kazuyoshi Hirota
Publikationsdatum
06.04.2016
Verlag
Springer Japan
Erschienen in
Journal of Anesthesia / Ausgabe 3/2016
Print ISSN: 0913-8668
Elektronische ISSN: 1438-8359
DOI
https://doi.org/10.1007/s00540-016-2171-8

Weitere Artikel der Ausgabe 3/2016

Journal of Anesthesia 3/2016 Zur Ausgabe

Short Communication

Hemodynamic monitoring and management in high-risk surgery: a survey among Japanese anesthesiologists

Original Article

Ultrasound-guided popliteal sciatic nerve blockade in the severely and morbidly obese: a prospective and randomized study

Short Communication

Impact of anesthetic technique on the stress response elicited by laparoscopic cholecystectomy: a randomized trial

Original Article

Comparison of remifentanil EC50 for facilitating i-gel and laryngeal mask airway insertion with propofol anesthesia

Review Article

Minimally invasive or noninvasive cardiac output measurement: an update

Clinical Report

Two cases of compartment syndrome of the lower extremities during surgery for gynecological malignancies

Neu im Fachgebiet AINS

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Häufigste Gründe für Brustschmerzen bei Kindern

06.05.2024 Pädiatrische Diagnostik Nachrichten

Akute Brustschmerzen sind ein Alarmsymptom par exellence, schließlich sind manche Auslöser lebensbedrohlich. Auch Kinder klagen oft über Schmerzen in der Brust. Ein Studienteam ist den Ursachen nachgegangen.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise